APA (7th ed.) Citation

Novak, D., Janota, B., Hörmann, A. A., Sawicka, A., Kroselj, M., Hubalewska-Dydejczyk, A., . . . Garnuszek, P. (2023). Development of the 99m Tc-Labelled SST 2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study. Pharmaceutics, 15(3), 885. https://doi.org/10.3390/pharmaceutics15030885

Chicago Style (17th ed.) Citation

Novak, Doroteja, et al. "Development of the 99m Tc-Labelled SST 2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study." Pharmaceutics 15, no. 3 (2023): 885. https://doi.org/10.3390/pharmaceutics15030885.

MLA (9th ed.) Citation

Novak, Doroteja, et al. "Development of the 99m Tc-Labelled SST 2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study." Pharmaceutics, vol. 15, no. 3, 2023, p. 885, https://doi.org/10.3390/pharmaceutics15030885.